| http://www.w3.org/ns/prov#value | - Indication: The FDA announced the approval of Tudorza Pressair (aclidinium bromide inhalation powder) for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
|
